Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Launched by NANJING MEDICAL UNIVERSITY · Apr 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called thymosin alpha 1 for patients with acute aortic syndrome (AAS), which is a serious condition affecting the aorta, the main artery in the body. The goal of the study is to see if thymosin alpha 1 can help prevent complications like systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS), which can be life-threatening. Researchers believe that giving this treatment during the early stages of AAS may reduce these risks.

To participate in the trial, individuals must be between 18 and 90 years old and have been diagnosed with acute aortic syndrome within the last two weeks. They should also be planning to undergo emergency surgery for their condition. However, some people may not be eligible, such as those who are allergic to thymosin alpha 1, pregnant or breastfeeding women, and individuals with certain mental health issues or substance abuse problems. If you decide to join the study, you'll be asked to sign a consent form and will receive regular monitoring during the trial to assess your health and response to treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
• • Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.
• • The patients' age between 18 \~90 years old.
• • Agree to participate in the study and sign the informed consent.
• Exclusion Criteria:
• • Patients allergic to Thymosin α1;
• • Lactating women and pregnant women;
• • Patients with mental diseases, drug and alcohol dependence;
• • Refuse to participate in this study and refuse to sign the informed consent.